BRPI0812064A2 - Formulação farmacêutica, tabletes, e, processo para a produção de uma formulação farmacêutica - Google Patents

Formulação farmacêutica, tabletes, e, processo para a produção de uma formulação farmacêutica

Info

Publication number
BRPI0812064A2
BRPI0812064A2 BRPI0812064-1A2A BRPI0812064A BRPI0812064A2 BR PI0812064 A2 BRPI0812064 A2 BR PI0812064A2 BR PI0812064 A BRPI0812064 A BR PI0812064A BR PI0812064 A2 BRPI0812064 A2 BR PI0812064A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical formulation
tables
production
formulation
pharmaceutical
Prior art date
Application number
BRPI0812064-1A2A
Other languages
English (en)
Inventor
Karl Kolter
Michael Schoenherr
Silke Gebert
Kathrin Meyer-Boehm
Angelika Maschke
Original Assignee
Basf Se
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Se filed Critical Basf Se
Publication of BRPI0812064A2 publication Critical patent/BRPI0812064A2/pt
Publication of BRPI0812064B1 publication Critical patent/BRPI0812064B1/pt
Publication of BRPI0812064B8 publication Critical patent/BRPI0812064B8/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
BRPI0812064A 2007-06-06 2008-06-03 formulação farmacêutica na forma de aglomerados, comprimidos, e, processo para a produção de uma formulação farmacêutica BRPI0812064B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07109722 2007-06-06
PCT/EP2008/056805 WO2008148742A2 (de) 2007-06-06 2008-06-03 Pharmazeutische formulierung für die herstellung von schnell zerfallenden tabletten

Publications (3)

Publication Number Publication Date
BRPI0812064A2 true BRPI0812064A2 (pt) 2014-11-25
BRPI0812064B1 BRPI0812064B1 (pt) 2019-08-13
BRPI0812064B8 BRPI0812064B8 (pt) 2021-05-25

Family

ID=39643971

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0812064A BRPI0812064B8 (pt) 2007-06-06 2008-06-03 formulação farmacêutica na forma de aglomerados, comprimidos, e, processo para a produção de uma formulação farmacêutica

Country Status (11)

Country Link
US (1) US10406105B2 (pt)
EP (1) EP2164462B1 (pt)
JP (2) JP5627455B2 (pt)
KR (2) KR101903781B1 (pt)
CN (1) CN101707930B (pt)
AU (1) AU2008258627A1 (pt)
BR (1) BRPI0812064B8 (pt)
CA (1) CA2686964A1 (pt)
ES (1) ES2639130T3 (pt)
MX (1) MX2009013063A (pt)
WO (1) WO2008148742A2 (pt)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
AUPS088702A0 (en) * 2002-03-04 2002-03-28 Borody, Thomas Julius Electrolyte purgative
UA95093C2 (uk) 2005-12-07 2011-07-11 Нікомед Фарма Ас Спосіб одержання кальцієвмісної сполуки
MX2009013063A (es) 2007-06-06 2010-01-15 Basf Se Formulacion farmaceutica para la produccion de tabletas de desintegracion rapida.
EP2164460B1 (de) 2007-06-06 2017-08-09 Basf Se Pharmazeutische formulierung für die herstellung von schnell zerfallenden tabletten
CN102988318A (zh) * 2008-11-25 2013-03-27 田边三菱制药株式会社 口腔速崩片及其制备方法
TW201028168A (en) * 2008-12-19 2010-08-01 Solvay Pharm Bv Precompacted fast-disintegrating formulations of compounds with a low oral bioavailability
TWI455733B (zh) * 2009-03-30 2014-10-11 Toray Industries 口腔內崩壞性被覆錠劑
WO2010119851A1 (ja) * 2009-04-14 2010-10-21 ライオン株式会社 口腔内崩壊錠
JP6073543B2 (ja) * 2010-07-08 2017-02-01 沢井製薬株式会社 ロラタジン含有口腔内崩壊錠の製造方法
EP3424515A3 (en) 2010-08-04 2019-06-19 Thomas Julius Borody Stool collection devices and methods for using them
AU2011342368B2 (en) 2010-12-13 2016-11-17 Rite-Prep Pty Ltd Gastric and colonic formulations and methods for making and using them
CN107252419A (zh) * 2010-12-22 2017-10-17 巴斯夫欧洲公司 快速崩解的固体包衣剂型
US8715729B2 (en) 2010-12-22 2014-05-06 Basf Se Rapidly disintegrating, solid coated dosage form
US9968638B2 (en) 2011-03-09 2018-05-15 Regents Of The University Of Minnesota Compositions and methods for transplantation of colon microbiota
JP6245786B2 (ja) * 2011-10-17 2017-12-13 大同化成工業株式会社 医薬用結合剤及び該結合剤を用いた製剤
IN2014DN07797A (pt) 2012-03-29 2015-05-15 Daicel Corp
US9719144B2 (en) 2012-05-25 2017-08-01 Arizona Board Of Regents Microbiome markers and therapies for autism spectrum disorders
WO2013181694A1 (en) 2012-06-04 2013-12-12 Gaurav Agrawal Compositions and methods for treating crohn's disease and related conditions and infections
PT2877163T (pt) 2012-07-27 2019-05-24 Redhill Biopharma Ltd Formulações e métodos de fabrico de formulações para utilização na evacuação colónica
JP6230539B2 (ja) 2012-09-20 2017-11-15 株式会社ダイセル 酸型カルボキシメチルセルロース及び結晶セルロースを含む崩壊性粒子組成物及び該組成物を含む口腔内崩壊錠剤
ITMI20121628A1 (it) * 2012-09-28 2014-03-29 Pharmafilm Srl Film orodisperdibili autosupportanti a rapida dissoluzione per uso terapeutico o alimentare
WO2014176632A1 (en) 2013-04-30 2014-11-06 Borody Thomas J Compositions and methods for treating microbiota-related psychotropic conditions and diseases
WO2015046223A1 (ja) * 2013-09-27 2015-04-02 株式会社ダイセル 二段階の湿式造粒工程で製造される崩壊性粒子組成物及び該組成物を含む口腔内崩壊錠剤
EP3135300B1 (en) 2014-04-21 2022-03-30 Daicel Corporation Disintegrating particle composition including microfibrous cellulose
EP3206671B1 (en) * 2014-10-16 2024-06-12 Cargill, Incorporated Process for preparing a directly compressible erythritol and uses thereof
BR112017024264B1 (pt) 2015-05-14 2022-07-12 Crestovo Holdings Llc Composições para transplante de flora fecal e métodos de preparação e utilização das mesmas, e dispositivos para sua administração
KR102534545B1 (ko) 2015-05-22 2023-05-18 아리조나 보드 오브 리젠츠 온 비하프 오브 아리조나 스테이트 유니버시티 자폐 스펙트럼 장애 및 관련된 증상을 치료하는 방법
US11214773B2 (en) 2015-09-24 2022-01-04 San Diego State University (Sdsu) Foundation Antibacterial and protective bacteriophage formulations and methods for making and using them
US20170360848A1 (en) 2016-06-15 2017-12-21 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
US10849936B2 (en) 2016-07-01 2020-12-01 Regents Of The University Of Minnesota Compositions and methods for C. difficile treatment
US20180036352A1 (en) 2016-08-03 2018-02-08 Crestovo Holdings Llc Methods for treating ulcerative colitis
WO2018071537A1 (en) 2016-10-11 2018-04-19 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
US10092601B2 (en) 2016-10-11 2018-10-09 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
WO2018071536A1 (en) 2016-10-11 2018-04-19 Crestovo Holdings Llc Compositions and methods for treating primary sclerosing cholangitis and related disorders
US11040073B2 (en) 2017-04-05 2021-06-22 Finch Therapeutics Holdings Llc Compositions and methods for treating diverticulitis and related disorders
EP3606541A1 (en) 2017-04-05 2020-02-12 Crestovo Holdings LLC Compositions and methods for treating parkinson's disease (pd) and related disorders
JP2020521760A (ja) 2017-05-26 2020-07-27 クレストヴォ・ホールディングス・エルエルシー 糞便微生物ベースの治療剤を含む凍結乾燥組成物ならびにそれを製造および使用する方法
JP2020530494A (ja) 2017-08-07 2020-10-22 フィンチ セラピューティクス、インコーポレイテッド. 健康な腸バリアを維持及び回復するための組成物及び方法
US11166990B2 (en) 2018-07-13 2021-11-09 Finch Therapeutics Holdings Llc Methods and compositions for treating ulcerative colitis
EP3856212A1 (en) 2018-09-27 2021-08-04 Finch Therapeutics Holdings LLC Compositions and methods for treating epilepsy and related disorders
WO2020211915A1 (en) * 2019-04-17 2020-10-22 Nordiccan A/S Fast disintegrating cannabinoid tablets
US11633351B2 (en) * 2019-12-13 2023-04-25 Nordiccan A/S Fast disintegrating cannabinoid tablets
PH12021553137A1 (en) 2019-07-19 2022-07-25 Finch Therapeutics Holdings Llc Methods and products for treatment of gastrointestinal disorders
US11179331B1 (en) * 2020-04-21 2021-11-23 Cure Pharmaceutcai Holding Corp Oral soluble film containing sildenafil citrate

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3434138A1 (de) 1984-09-18 1986-03-27 Basf Ag, 6700 Ludwigshafen Verfahren zur herstellung von unloeslichen, nur wenig quellbaren pulverfoermigen polymerisaten
US5569469A (en) 1984-10-16 1996-10-29 Vectorpharma International, S.P.A. Poorly soluble medicaments supported on polymer substances in a form suitable for increasing their dissolving rate
GB8518301D0 (en) 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
CA2159419C (en) 1994-10-17 2006-07-04 Pieter De Haan Solid pharmaceutical composition comprising an excipient capable of binding water
US5879342A (en) 1996-10-21 1999-03-09 Kelley; Gregory S. Flexible and reinforced tubing
EP0839526A3 (en) 1996-10-31 1999-01-07 Takeda Chemical Industries, Ltd. Solid pharmaceutical preparation with fast buccal disintegration or dissolution
JP2001504342A (ja) 1996-11-15 2001-04-03 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 成形されたまたは未成形のポリオール材料の製造方法
DE19709663A1 (de) * 1997-03-10 1998-09-17 Basf Ag Verwendung von redispergierbaren Polymerpulvern oder Polymergranulaten als Bindemittel zur Herstellung von festen pharmazeutischen Darreichungsformen
US5874418A (en) 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
FR2781152B1 (fr) 1998-07-20 2001-07-06 Permatec Tech Ag Utilisation d'un polymere de type acrylique en tant qu'agent de desagregation
TW585786B (en) * 1998-07-28 2004-05-01 Takeda Chemical Industries Ltd Lansoprazole-containing rapidly disintegrable solid pharmaceutical composition
DE19912031A1 (de) 1999-03-17 2000-09-21 Basf Ag Verwendung von quervernetztem Polyvinylpyrrolidon zur Erhöhung der Zerfallgeschwindigkeit von kompakten teilchenförmigen Wasch- und Reinigungsmitteln
US20020071864A1 (en) * 1999-03-25 2002-06-13 Yuhan Corporation Rapidly disintegrable tablet for oral administration
US6495177B1 (en) 1999-08-13 2002-12-17 Warner Chilcott Laboratories Ireland Limited Orally dissolvable nutritional supplement
DE10011137A1 (de) 2000-03-10 2001-09-13 Basf Ag Verfahren zur Einstellung der Teilchengröße von Popcornpolymeren während der Popcornpolymerisation
US20020147232A1 (en) * 2000-05-26 2002-10-10 Claus Sundgreen Pharmaceutical compositions comprising desglymidodrine as an active drug substance
US7147869B2 (en) 2000-12-07 2006-12-12 Altana Pharma Ag Rapidly disintegrating tablet comprising an acid-labile active ingredient
UA80393C2 (uk) 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці
US20020127277A1 (en) 2000-12-22 2002-09-12 Yihong Qiu Solid dosage forms of divalproex sodium
EP1429736A2 (en) * 2001-09-26 2004-06-23 Pharmacia Corporation Organoleptically acceptable intraorally disintegrating compositions
GB0124953D0 (en) 2001-10-17 2001-12-05 Novartis Ag Organic Compounds
FR2831820B1 (fr) * 2001-11-05 2004-08-20 Ethypharm Sa Comprime orodispersible presentant une grande homogeneite et son procede de preparation
US6723348B2 (en) 2001-11-16 2004-04-20 Ethypharm Orodispersible tablets containing fexofenadine
US7118765B2 (en) 2001-12-17 2006-10-10 Spi Pharma, Inc. Co-processed carbohydrate system as a quick-dissolve matrix for solid dosage forms
EP1455813B1 (en) 2001-12-18 2015-07-15 mondoBIOTECH AG Interferon gamma in combination with a diagnostic array for use in the improved treatment of idiopathic pulmonary fibrosis
BRPI0307786B8 (pt) * 2002-02-26 2021-05-25 Astrazeneca Ab composição farmacêutica, método para preparar a mesma, métodos para inibir a taxa de precipitação do agente da solução no trato gi, e para reduzir variabilidade inter-pacientes no que se refere à biodisponibilidade e/ou concentrações plásmáticas do agente, e, uso de um celulose éter solúvel em água ou de um éster de um celulose éter solúvel em água
GB0204771D0 (en) * 2002-02-28 2002-04-17 Phoqus Ltd Fast disintegrating tablets
JP2004026521A (ja) 2002-06-21 2004-01-29 Mitsubishi Chemicals Corp フラーレンの製造設備及びフラーレンの製造方法
JP2006508134A (ja) 2002-11-08 2006-03-09 グラクソ グループ リミテッド 医薬組成物
WO2004073687A1 (en) * 2003-02-19 2004-09-02 H. Lundbeck A/S Method for preparation of an agglomerate using melt agglomeration
JP2004265216A (ja) 2003-03-03 2004-09-24 Seiko Epson Corp 印刷装置、受信装置、中継装置、印刷システムおよび印刷方法
US8545881B2 (en) 2004-04-19 2013-10-01 Eurand Pharmaceuticals, Ltd. Orally disintegrating tablets and methods of manufacture
US20050244343A1 (en) 2004-04-30 2005-11-03 Withiam Michael C Oral care products comprising silica
US20050244492A1 (en) * 2004-04-30 2005-11-03 Mehra Dev K Rapidly disintegrating tablets comprising titanium dioxide
JP2006076971A (ja) * 2004-09-13 2006-03-23 Basf Ag 口腔内崩壊錠
JP4446177B2 (ja) * 2005-01-21 2010-04-07 東和薬品株式会社 耐湿性口腔内崩壊錠の製造方法
ES2403167T3 (es) * 2005-12-21 2013-05-14 Basf Se Polivinilpirrolidona entrelazada finamente dividida como agente desintegrador de tabletas
US8425935B2 (en) 2005-12-21 2013-04-23 Basf Se Pharmaceutical formulation for producing rapidly disintegrating tablets
MX2009013063A (es) 2007-06-06 2010-01-15 Basf Se Formulacion farmaceutica para la produccion de tabletas de desintegracion rapida.
CN102046147B (zh) 2007-06-06 2013-03-20 巴斯夫欧洲公司 用于制备快速崩解的片剂的药物配制剂
JP2010529073A (ja) 2007-06-06 2010-08-26 ビーエーエスエフ ソシエタス・ヨーロピア チュアブル錠及びトローチ剤製造のための医薬製剤
EP2164460B1 (de) 2007-06-06 2017-08-09 Basf Se Pharmazeutische formulierung für die herstellung von schnell zerfallenden tabletten
DE102008038678B4 (de) * 2008-08-12 2012-03-08 Continental Automotive Gmbh Verfahren und Vorrichtung zum Schätzen einer Emission mindestens einer Abgaskomponente

Also Published As

Publication number Publication date
JP2014114322A (ja) 2014-06-26
KR101903781B1 (ko) 2018-11-13
EP2164462A2 (de) 2010-03-24
EP2164462B1 (de) 2017-05-31
BRPI0812064B1 (pt) 2019-08-13
KR20100028624A (ko) 2010-03-12
WO2008148742A2 (de) 2008-12-11
MX2009013063A (es) 2010-01-15
KR20160083132A (ko) 2016-07-11
JP2010529074A (ja) 2010-08-26
ES2639130T3 (es) 2017-10-25
AU2008258627A1 (en) 2008-12-11
BRPI0812064B8 (pt) 2021-05-25
CN101707930B (zh) 2013-10-30
WO2008148742A3 (de) 2009-08-13
JP5627455B2 (ja) 2014-11-19
CN101707930A (zh) 2010-05-12
CA2686964A1 (en) 2008-12-11
US10406105B2 (en) 2019-09-10
US20100178349A1 (en) 2010-07-15

Similar Documents

Publication Publication Date Title
BRPI0812064A2 (pt) Formulação farmacêutica, tabletes, e, processo para a produção de uma formulação farmacêutica
BRPI0905717A2 (pt) Composição farmacêutica, processo para preparar uma composição farmacêutica e forma de dosagem farmacêutica
BRPI0818533A2 (pt) composto, composição farmacêutica, e, processo para a preparação de um composto
PT2799089T (pt) Processo para produzir uma formulação farmacêutica de agentes de contraste
BRPI0919192A2 (pt) Uso de lipídio, composição nutricional, e, processo para a produção de uma composição nutricional
BRPI0818541A2 (pt) Processo para a produção de um produto farmacêutico
BRPI0817423A2 (pt) Processos para a preparação de um composto, para a preparação de uma formulação farmacêutica, e para a preparação de um intermediário de um composto, e, composto
BRPI1014865A2 (pt) "composição e formulação farmacêutica comreendendo derivados de nitrocatecol, e, método para fabricar uma composição ou formulação farmacêutica"
BRPI0920955A2 (pt) processo para a preparação de uma composição polimérica , composição polimérica, misturas, e, uso da composição polimérica
BRPI0915084A2 (pt) composto, processo para a preparação de um composto, composição farmacêutica, uso de um composto, métodos para a profilaxia ou tratamento de um estado de doença ou uma condição e de câncer
BRPI0815138A2 (pt) Métodos e organismos para a produção acoplada a crescimento de 1,4-butanodiol
BR112012000421A2 (pt) composições e métodos para intensificar a produção de um produto biológico.
BRPI1007161A2 (pt) composição farmacêutica oral, e processo para preparar uma composição
PT2639223T (pt) Processos para produção de ácidos cicloalquilcarboxamido-piridinabenzoicos
FI20070569A0 (fi) Uusi stabiili tuote ja menetelmä sen valmistamiseksi
BRPI0905847A2 (pt) "composição farmacêutica injetável e processo para preparar a composição"
BRPI0817747A2 (pt) Processo para a preparação de derivados de ácido 2-di-halogenoacil-3-amino-acrílico
BRPI0814821A2 (pt) Composto, composição farmacêutica, e, processo para preparar um composto
BR112012010007A2 (pt) processo para fabricação de uma composição biodegradável, composição biodegradável, artigo biodegradável e uso da composição
BR112012008202A2 (pt) processo de preparação de uma composição, componentes e uso da composição
BRPI0818781A2 (pt) Processo para a preparação de uma bebida fermentada
BR112012021066A2 (pt) processo de preparação de uma composição, composição e aplicação da composição
BRPI0811788A2 (pt) Composição de proteína vegetal, processo para a fabricação de uma composição de proteína vegetal e produto alimentício
BRPI0807001A2 (pt) Formulação farmacêutica, e, método para preparação de uma formulação farmacêutica.
BRPI1008340A2 (pt) forma cristalina, composição farmacêutica, processos para fabricar uma composição farmacêutica e uma forma, uso da forma cristalina, e, método para tratar uma condição de doença

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 13/08/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 13/08/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/06/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B22B Petition not considered [chapter 22.2 patent gazette]

Free format text: NAO CONHECIDA A PETICAO NO 870210067135, DE 23/07/2021, EM VIRTUDE DO DISPOSTO NO ART. 219 , INCISO II DA LPI